Home About us Contact
|
Home About us Contact | ||
|
|
||
Regular Evaluation (regular + evaluation)
Selected AbstractsMulticenter quality control of the detection of HIV-1 genome in semen before medically assisted procreationJOURNAL OF MEDICAL VIROLOGY, Issue 7 2006Christophe Pasquier Abstract Couples in whom the man is HIV-1-positive may use medically assisted procreation in order to conceive a child without contaminating the female partner. But, before medically assisted procreation, the semen has to be processed to exclude HIV and tested for HIV nucleic acid before and after processing. The performance was evaluated of the technical protocols used to detect and quantify HIV-1 in 11 centers providing medically assisted procreation for couples with HIV-1 infected men by testing panels of seminal plasma and cells containing HIV-1 RNA and/or DNA. The performance of these tests varied due to the different assays used. False positive results were obtained in 14,19% of cases. The sensitivity for RNA detection in seminal plasma was 500,1,000 RNA copies/ml, over 500 RNA copies/106 cells in semen cells, and for DNA detection in semen cells 50,500 DNA copies/106 cells. The use of silica-based extraction seemed to increase the assay performance, whereas the use of internal controls to detect PCR inhibitor did not. This first quality control highlights the need for technical improvements of the assays to detect and quantify HIV in semen fractions and for regular evaluation of their performance. J. Med. Virol. 78:877,882, 2006. © 2006 Wiley-Liss, Inc. [source] Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidismJOURNAL OF PAEDIATRICS AND CHILD HEALTH, Issue 11 2005EA Geelhoed Objective: To evaluate the costs and benefits of neonatal screening for phenylketonuria (PKU) and congenital hypothyroidism (CH). Neonatal screening for PKU and CH is common throughout the developed world. It represents a model of preventive care in that the screening procedure is simple and intellectual disability is otherwise irreversible. Changes in treatment and care, and in particular the advent of maternal PKU, require regular evaluation of a programme that also impacts on a large healthy population. Method: Costs of screening were based on the programme provided within Western Australia. Costs averted were derived using patterns of care currently adopted in Western Australia and applied according to historical patterns of intellectual disability for each condition. Results: A net saving of $A2.9 million is attributable to the programme annually. The economic benefits derive from the prevention of intellectual disability which otherwise incurs costs throughout the life of the affected individual. Maternal PKU represented a minor proportion of overall costs. Sensitivity analysis showed that the cost savings were robust, given changes in the levels of intellectual disability, but varied according to the discount rate. The result of a net saving was evident under all assumptions. Conclusion: Neonatal screening for PKU and CH is a cost saving use of resources and the emergence of maternal PKU has not had a significant effect on the economic outcomes. [source] Safely treating hypokalaemia in high dependency cardiac surgical patientsNURSING IN CRITICAL CARE, Issue 6 2006Claire Sladdin Abstract In Australia, there were national issues on the use of potassium ampoules (resulting in patient deaths), which led to the removal of the ampoules from clinical areas. A decision was made by the Medication Safety Committee at a metropolitan Melbourne hospital to remove potassium ampoules from ward areas as part of the establishment of a hospital-wide potassium guideline. As a result, the nurses in the cardiothoracic ward Practice Review Committee identified the need to review the proposed practice of treating hypokalaemia with 30 mmol of potassium chloride (KCL) in 1000 mL over an extended period in postoperative cardiothoracic patients. The challenge was to develop a practice to safely administer intravenous KCL in fluid restricted patients in addition to the hospital guidelines to prevent hypokalaemic-induced cardiac dysrhythmias. A literature search revealed there were no clear or uniform approaches to guide our practice in addressing this clinical problem. The Practice Review Committee developed a KCL administration guideline based on a review of the available literature. The Practice Review Committee developed a ward-based guideline that addressed infusion concentration, duration of administration, responsiveness of nurses to severity of hypokalaemia and the evaluation of treatment by measuring serum potassium after replacement. This ward-based guideline was based on benchmarking from similar institutions and relevant literature. The review process provided an opportunity for the staff to critique their practice to improve patient care and allowed regular evaluation of the implemented practice guideline. The ward-based guideline required a revision as patients' renal function was not being taken into consideration prior to potassium infusions being administered. The implementation of the ward-based guideline into practice has been well received by the staff as it has allowed consistent practice and timely treatment of hypokalaemia. [source] Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: A retrospective study of the risk factorsPEDIATRIC TRANSPLANTATION, Issue 7 2009Hoi Soo Yoon Abstract:, CMV infection is one of the major causes of morbidity and mortality after HSCT. The aim of this single center retrospective study was to analyze risk factors for CMV infection in pediatric patients who underwent HSCT. We retrospectively reviewed the medical records of 117 pediatric patients who underwent allogeneic HSCT at Asan Medical Center between December 2000 and January 2007. After HSCT, CMV antigenemia was detected by identifying CMV pp65 early antigen in white blood cells. The incidence of CMV antigenemia was 24% (28/117) at a median of 38 days (range: 19,123 days) after HSCT. In multivariate analysis, CMV antigenemia occurred significantly more often in CMV seropositive recipients, patients who received grafts from alternative donors, T-cell depleted grafts, patients on ATG-containing conditioning regimens, or patients who received steroid for acute GVHD (p < 0.05). CMV antigenemia tend to develop earlier in patients who received ATG-containing conditioning regimens (p = 0.09). A second episode of CMV antigenemia was observed in three out of 28 patients (11%). The incidence of CMV disease was 5.9% (7/117) at a median of 97 days (range: 34,120 days). Manifestation of CMV disease included retinitis in two, pneumonitis in two, hepatitis in one, hepatitis with colitis in one, and gastritis in one. Six of the 12 patients (50%) with HG antigenemia (CMV pp65 antigen positivity ,40 cells) developed clinical CMV disease, a rate that was significantly higher than seen in patients with LG antigenemia (6.25%; p < 0.01). We recommend that patients with these risk factors should carefully undergo regular evaluations for CMV infection. We also suggest that earlier and more aggressive preemptive treatment and serial follow-up of CMV disease is necessary in patients with HG-antigenemia. [source] | ||||||||||